NWBO Northwest Biotherapeutics, Inc.
-
Northwest Biotherapeutics Reported Earnings
Friday, November 13, 2026 · 12:00 AM ET
Northwest Biotherapeutics (NWBO) reported a loss of $0.02 per share on revenue of $0.88 million for the . . Revenue grew 341.50% on a year-over-year basis.
Northwest Biotherapeutics Inc is a development stage biotechnology company engaged in the development of immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($0.02)
Earnings Whisper®
—
Consensus Estimate
—
Earnings Surprise
Earnings Growth
Reported Revenue
$0.88M
Revenue Estimate
—
Revenue Surprise
Revenue Growth